Drug search by name

Belinostat Intravenous and Hepatic impairment

Result of checking the interaction of drug Belinostat Intravenous and disease Hepatic impairment for safety when used together.

Check result:

Belinostat Intravenous <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Belinostat is metabolized by the liver, primarily by hepatic UGT1A1. Hepatic impairment is expected to increase exposure to belinostat, which can result in fatal hepatotoxicity and liver function test abnormalities. Reduce the starting dose of belinostat to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. There is insufficient data to recommend a dose of belinostat in patients with moderate and severe hepatic impairment. It is recommended to monitor liver function tests before treatment and before the start of each cycle and to interrupt or adjust dosage until recovery, or permanently discontinue belinostat based on the severity of the hepatic toxicity. Care should be taken when using belinostat in these patients.

Belinostat Intravenous

Generic Name: belinostat

Brand Name: Beleodaq

Synonyms: Belinostat

What is Belinostat Intravenous?